120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
康替唑胺与利奈唑胺在5期慢性肾脏病中的血液学安全性比较：一项主动对照新使用者回顾性队列研究
Authors Zhang W, Cai X, Hou R, Guo J , Ma Y, Kang J, Li X
Received 27 October 2025
Accepted for publication 23 January 2026
Published 30 January 2026 Volume 2026:20 576881
DOI https://doi.org/10.2147/DDDT.S576881
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tuo Deng
Wenjun Zhang,1,* Xinfeng Cai,2,* Ruigang Hou,1 Jinlin Guo,3 Ying Ma,4 Jianbang Kang,1 Xingang Li5
1Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Department of Pharmacy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 3The Fifth Clinical Medical College of Shanxi Medical University/Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, People’s Republic of China; 4State Institution of Drug Clinical Trials, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, People’s Republic of China; 5Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ruigang Hou, Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030012, People’s Republic of China, Email houruigang01@163.com Jinlin Guo, The Fifth Clinical Medical College of Shanxi Medical University/Shanxi Provincial People’s Hospital, Shuangtasi Street 59#, Taiyuan, Shanxi, 030012, People’s Republic of China, Email guojinlin@sxmu.edu.cn
Introduction: Contezolid is a novel oxazolidinone antibiotic approved for treating Gram-positive bacterial infections. Unlike linezolid, it lacks myelosuppressive toxicity, a potential advantage in patients with renal failure who are prone to anemia. However, data on hematologic safety of contezolid in this population remains limited. This study evaluates the hematological effects of contezolid in patients with renal failure.
Methods: This two-center retrospective cohort study employed an active-comparator new-user design to compare the hematological safety of contezolid versus linezolid in patients with renal failure. The primary outcome was the impact of contezolid and linezolid on hemoglobin levels. The secondary outcomes included microbial eradication, clinical cure rate and adverse reaction. Propensity score matching and multivariate logistic regression were used to adjust for confounding factors.
Results: A total of 290 patients were enrolled, with 122 in the contezolid group and 168 in the linezolid group. Severe anemia occurred in 14.75% of patients receiving contezolid versus 46.43% with linezolid (P < 0.001). No significant differences in platelet count (P = 0.072), clinical cure rate (P = 0.878), procalcitonin levels (P = 0.432), or microbial eradication rates (P = 0.411) were observed between the contezolid and linezolid groups after treatment. Multivariate-adjusted logistic analysis further illustrated that, compared to contezolid, linezolid was associated with a higher risk of severe anemia (adjusted odds ratio: 2.29; 95% CI: 1.64– 3.35), with a treatment duration cutoff of 7 days.
Conclusion: Compared with linezolid, contezolid was associated with a lower risk of clinically significant hemoglobin decline among patients with renal failure.
Keywords: contezolid, linezolid, renal failure, myelosuppression, hemoglobin
1Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Department of Pharmacy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 3The Fifth Clinical Medical College of Shanxi Medical University/Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, People’s Republic of China; 4State Institution of Drug Clinical Trials, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, People’s Republic of China; 5Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ruigang Hou, Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030012, People’s Republic of China, Email houruigang01@163.com Jinlin Guo, The Fifth Clinical Medical College of Shanxi Medical University/Shanxi Provincial People’s Hospital, Shuangtasi Street 59#, Taiyuan, Shanxi, 030012, People’s Republic of China, Email guojinlin@sxmu.edu.cn
Introduction: Contezolid is a novel oxazolidinone antibiotic approved for treating Gram-positive bacterial infections. Unlike linezolid, it lacks myelosuppressive toxicity, a potential advantage in patients with renal failure who are prone to anemia. However, data on hematologic safety of contezolid in this population remains limited. This study evaluates the hematological effects of contezolid in patients with renal failure.
Methods: This two-center retrospective cohort study employed an active-comparator new-user design to compare the hematological safety of contezolid versus linezolid in patients with renal failure. The primary outcome was the impact of contezolid and linezolid on hemoglobin levels. The secondary outcomes included microbial eradication, clinical cure rate and adverse reaction. Propensity score matching and multivariate logistic regression were used to adjust for confounding factors.
Results: A total of 290 patients were enrolled, with 122 in the contezolid group and 168 in the linezolid group. Severe anemia occurred in 14.75% of patients receiving contezolid versus 46.43% with linezolid (P < 0.001). No significant differences in platelet count (P = 0.072), clinical cure rate (P = 0.878), procalcitonin levels (P = 0.432), or microbial eradication rates (P = 0.411) were observed between the contezolid and linezolid groups after treatment. Multivariate-adjusted logistic analysis further illustrated that, compared to contezolid, linezolid was associated with a higher risk of severe anemia (adjusted odds ratio: 2.29; 95% CI: 1.64– 3.35), with a treatment duration cutoff of 7 days.
Conclusion: Compared with linezolid, contezolid was associated with a lower risk of clinically significant hemoglobin decline among patients with renal failure.
Keywords: contezolid, linezolid, renal failure, myelosuppression, hemoglobin